Horizon Technology Finance, an affiliate of Monroe Capital and specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services and sustainability industries, has provided a $35 million venture loan facility to GT Medical Technologies (GT MedTech), of which $15 million has been initially funded.
“GT MedTech is pioneering brain tumor treatment with its FDA-cleared GammaTile,” Gerald A. Michaud, president of Horizon Technology, said. “This solution will help transform the standard of care, while offering a cost-effective reimbursement profile to hospitals, creating a clear win for all stakeholders in the healthcare ecosystem.”
“We are delighted to have Horizon’s support as we expand the reach of our groundbreaking GammaTile solution,” Per Langoe, CEO of GT MedTech, said. “By delivering targeted radiation immediately after tumor removal, GammaTile provides focused radiation to the tumor cavity, helping eradicate residual tumor cells. Our partnership with Horizon Technology Finance will allow us to continue our strategic commercial and market expansion initiatives, helping bring GammaTile to more patients in need.”
